Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications

被引:250
作者
Bierhaus, A. [1 ]
Nawroth, P. P. [1 ]
机构
[1] Heidelberg Univ, Dept Med & Clin Chem 1, D-69120 Heidelberg, Germany
关键词
AGE; Diabetes; Glycation; HMGB1; Inflammation; Innate immunity; NF-kappa B; RAGE; Review; S100; GLYCATION END-PRODUCTS; ALTERS ANTIOXIDANT DEFENSES; CELL-SURFACE RECEPTOR; MOBILITY GROUP BOX-1; NF-KAPPA-B; SOLUBLE RECEPTOR; SERUM-LEVELS; CYTOPLASMIC DOMAIN; MODIFIED PROTEINS; ENDPRODUCTS RAGE;
D O I
10.1007/s00125-009-1458-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The pattern recognition receptor or receptor for AGE (RAGE) is constitutionally expressed in a few cell types only. However in almost all cells studied so far it is induced by reactions known to initiate inflammation. Its biological activity seems to be mainly dependent on the presence of its various ligands, including AGE, S100-calcium binding protein/calgranulins, high-mobility group protein 1, amyloid-beta-peptides and the family of beta-sheet fibrils, all known to be elevated in chronic metabolic, malignant and inflammatory diseases. The RAGE pathway interacts with cytokine-, lipopolysaccharide-, oxidised LDL-and glucose-triggered cellular reactions by turning a short-lasting inflammatory response into a sustained change of cellular function driven by perpetuated activation of the proinflammatory transcription factor, nuclear factor kappaB. RAGE-mediated persistent cell activation is of pivotal importance in various experimental and clinical settings, including diabetes and its complications, neurodegeneration, ageing, tumour growth, and autoimmune and infectious inflammatory disease. Due to RAGE's central role in maintaining perpetuated cell activation, various therapeutic attempts to block RAGE or its ligands are currently under investigation. Despite broad experimental evidence for the role of RAGE in chronic disease, knowledge of its physiological function is still missing, limiting predictions about safety of long-term inhibition of RAGE x ligand interaction in chronic diseases.
引用
收藏
页码:2251 / 2263
页数:13
相关论文
共 106 条
[91]   RETRACTED: Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy (Retracted Article) [J].
Toth, Cory ;
Rong, Ling Ling ;
Yang, Christina ;
Martinez, Jose ;
Song, Fei ;
Ramji, Noor ;
Brussee, Valentine ;
Liu, Wei ;
Durand, Jeff ;
Nguyen, Minh Dang ;
Schmidt, Ann Marie ;
Zochodne, Douglas W. .
DIABETES, 2008, 57 (04) :1002-1017
[92]   RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis [J].
Turovskaya, Olga ;
Foell, Dirk ;
Sinha, Pratima ;
Vogl, Thomas ;
Newlin, Robbin ;
Nayak, Jonamani ;
Nguyen, Mien ;
Olsson, Anna ;
Nawroth, Peter P. ;
Bierhaus, Angelika ;
Varki, Nissi ;
Kronenberg, Mitchell ;
Freeze, Hudson H. ;
Srikrishna, Geetha .
CARCINOGENESIS, 2008, 29 (10) :2035-2043
[93]   ROLE OF TOLL-LIKE RECEPTORS 2 AND 4, AND THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS IN HIGH-MOBILITY GROUP BOX 1-INDUCED INFLAMMATION IN VIVO [J].
van Zoelen, Marieke A. D. ;
Yang, Huan ;
Florquin, Sandrine ;
Meijers, Joost C. M. ;
Akira, Shizuo ;
Arnold, Bernd ;
Nawroth, Peter P. ;
Bierhaus, Angelika ;
Tracey, Kevin J. ;
van der Poll, Tom .
SHOCK, 2009, 31 (03) :280-284
[94]  
Vander Jagt David L., 2008, Drug Metabolism and Drug Interactions, V23, P93
[95]   Receptor for advanced glycation end product expression in experimental diabetic retinopathy [J].
Wang, Yumei ;
Hagen, Filanziska Vom ;
Pfister, Frederick ;
Bierhaus, Angelika ;
Feng, Yuxi ;
Gans, Reinhold ;
Hammes, Hans-Peter .
MAILLARD REACTION: RECENT ADVANCES IN FOOD AND BIOMEDICAL SCIENCES, 2008, 1126 :42-45
[96]   RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes [J].
Wendt, T ;
Harja, E ;
Bucciarelli, L ;
Wu, Q ;
Lu, Y ;
Rong, LL ;
Jenkins, DG ;
Stein, G ;
Schmidt, AM ;
Yan, SF .
ATHEROSCLEROSIS, 2006, 185 (01) :70-77
[97]   RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy [J].
Wendt, TM ;
Tanji, N ;
Guo, JC ;
Kislinger, TR ;
Qu, W ;
Lu, Y ;
Bucciarelli, LG ;
Rong, LL ;
Moser, B ;
Markowitz, GS ;
Stein, G ;
Bierhaus, A ;
Liliensiek, B ;
Arnold, B ;
Nawroth, PP ;
Stern, DM ;
D'Agati, VD ;
Schmidt, AM .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (04) :1123-1137
[98]   Advanced oxidation protein products as a novel marker of oxidative stress in uremia [J].
WitkoSarsat, V ;
Friedlander, M ;
CapeillereBlandin, C ;
NguyenKhoa, T ;
Nguyen, NT ;
Zingraff, J ;
Jungers, P ;
DescampsLatscha, B .
KIDNEY INTERNATIONAL, 1996, 49 (05) :1304-1313
[99]   Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice [J].
Yamamoto, Y ;
Kato, I ;
Doi, T ;
Yonekura, H ;
Ohashi, S ;
Takeuchi, M ;
Watanabe, T ;
Yamagishi, S ;
Sakurai, S ;
Takasawa, S ;
Okamoto, H ;
Yamamoto, H .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (02) :261-268
[100]   What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose [J].
Yan, SD ;
Stern, D ;
Schmidt, AM .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1997, 27 (03) :179-181